Lukas Biomedical Inc. (TPEX:6814)
19.00
+0.70 (3.83%)
Sep 15, 2026, 1:56 PM CST
Lukas Biomedical Revenue
Lukas Biomedical had revenue of 78.44M TWD in the half year ending June 30, 2026, a decrease of -19.49%. This brings the company's revenue in the last twelve months to 170.01M, down -5.72% year-over-year. In the year 2025, Lukas Biomedical had annual revenue of 179.49M, down -5.44%.
Revenue (ttm)
170.01M
Revenue Growth
-5.72%
P/S Ratio
4.51
Revenue / Employee
n/a
Employees
87
Market Cap
766.30M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 179.49M | -10.34M | -5.44% |
| Dec 31, 2024 | 189.83M | -42.01M | -18.12% |
| Dec 31, 2023 | 231.83M | 47.05M | 25.46% |
| Dec 31, 2022 | 184.79M | 27.17M | 17.24% |
| Dec 31, 2021 | 157.62M | -23.79M | -13.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 709.37M |
| Meribank Biotech | 408.48M |
| Taiwan Advance Bio-Pharmaceutical | 348.54M |
| BioLASCO Taiwan | 258.04M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 238.08M |
| NatureWise Biotech & Medicals | 174.62M |
| Neith | 31.84M |